Expert Review of Molecular Diagnostics This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Progress in the field of noninvasive diagnostics for colorectal cancer: a systematic review for the accuracy of blood-based biomarkers for detection of advanced pre-cancerous lesions
CONCLUSION: Many different blood-based biomarkers have been assessed for detection of advanced pre-cancerous lesions, but few have progressed beyond the discovery stage. While some biomarkers have reported high sensitivity and specificity, larger prospective studies in unbiased intended-use screening populations are required for validation.PMID:38044883 | DOI:10.1080/14737159.2023.2290646 (Source: Expert Review of Molecular Diagnostics)
Source: Expert Review of Molecular Diagnostics - December 4, 2023 Category: Laboratory Medicine Authors: Rishabh Goyal Molla M Wassie Jean Winter Timothy Jh Lathlean Graeme P Young Erin L Symonds Source Type: research

Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease
Expert Rev Mol Diagn. 2023 Nov 29. doi: 10.1080/14737159.2023.2289553. Online ahead of print.ABSTRACTINTRODUCTION: In recent years exciting developments in disease modifying treatments for Alzheimer's disease (AD) have made accurate and timely diagnosis of this disease a priority. Blood biomarkers (BBMs) for amyloid pathology using improved immunoassay and mass spectrometry techniques have been an area of intense research for the last 10 years and are coming to the fore, as a real prospect to be used in the clinical diagnostics of the disease.AREAS COVERED: The following review will update and discuss blood biomarkers that...
Source: Expert Review of Molecular Diagnostics - November 29, 2023 Category: Laboratory Medicine Authors: Eleftheria Kodosaki Henrik Zetterberg Amanda Heslegrave Source Type: research

Molecular imaging of PARP in cancer: state-of-the-art
Expert Rev Mol Diagn. 2023 Nov 27. doi: 10.1080/14737159.2023.2287503. Online ahead of print.ABSTRACTINTRODUCTION: Poly-ADP-ribose-polymerase inhibitors (PARPi), which exploit the processes of so-called 'synthetic lethality,' have been successfully implemented in oncological practice. However, not all patients respond to PARPi, and there is an unmet need for noninvasive biomarkers suitable for patient selection and monitoring during PARPi therapy.AREAS COVERED: The first clinical applications of molecular imaging with positron emission tomography/computed tomography (PET/CT) with [18F]-FluorThanatrace ([18F]-FTT) and [18F]...
Source: Expert Review of Molecular Diagnostics - November 27, 2023 Category: Laboratory Medicine Authors: Luca Filippi Luca Urso Viviana Frantellizzi Katia Marzo Maria Cristina Marzola Orazio Schillaci Laura Evangelista Source Type: research

Diagnostics in skeletal muscle channelopathies
Expert Rev Mol Diagn. 2023 Nov 27:1-19. doi: 10.1080/14737159.2023.2288258. Online ahead of print.ABSTRACTINTRODUCTION: Skeletal muscle channelopathies (SMCs) are a heterogenous group of disorders, caused by mutations in skeletal ion channels leading to abnormal muscle excitability, resulting in either delayed muscle relaxation (myotonia) which characterizes non-dystrophic myotonias (NDMs), or membrane transient inactivation, causing episodic weakness, typical of periodic paralyses (PPs).AREAS COVERED: SMCs include myotonia congenita, paramyotonia congenita, and sodium-channel myotonia among NDMs, and hyper-normokalemic, h...
Source: Expert Review of Molecular Diagnostics - November 27, 2023 Category: Laboratory Medicine Authors: Alex Vicino Raffaella Brugnoni Lorenzo Maggi Source Type: research

Diagnostics in skeletal muscle channelopathies
Expert Rev Mol Diagn. 2023 Nov 27. doi: 10.1080/14737159.2023.2288258. Online ahead of print.ABSTRACTINTRODUCTION: Skeletal muscle channelopathies (SMCs) are a heterogenous group of disorders, caused by mutations in skeletal ion channels leading to abnormal muscle excitability, resulting in either delayed muscle relaxation (myotonia) which characterizes non-dystrophic myotonias (NDMs), or membrane transient inactivation, causing episodic weakness, typical of periodic paralyses (PPs).AREAS COVERED: SMC include myotonia congenita, paramyotonia congenita and sodium-channel myotonia among NDMs, and hyper-normokalemic, hypokale...
Source: Expert Review of Molecular Diagnostics - November 27, 2023 Category: Laboratory Medicine Authors: Alex Vicino Raffaella Brugnoni Lorenzo Maggi Source Type: research